News

FDA to revise labeling of ADHD medication to indicate weight loss risk
The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...
Neurology Advisor21h
Optic Neuropathy and Other Hidden Ocular Risks of GLP-1 RA Weight Loss Drugs
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.
US FDA to revise ADHD stimulants labels to warn of weight loss risk in children under 6
The U.S. Food and Drug Administration said on Monday it is revising the labeling of all extended-release stimulants used to ...
Just one hot dog a day could raise disease risk, study suggests, but some cite caveats
Study analyzing 77 research papers finds habitual consumption of processed foods increases chronic disease risk, challenging ...
KSL3d
FDA to revise ADHD stimulants labels to warn of weight loss risk in children under 6
The Food and Drug Administration is revising the labeling of all extended-release stimulants used to treat attention-deficit ...
FDA vaccine official restricted COVID vaccine approvals against the advice of agency staff
A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...
Here’s how to get GLP-1 drugs covered by employer health insurance
Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...
KPVI1d
FDA Will Now Require Labeling of ADHD Medication to Indicate Weight Loss Risk
The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...
Health and Me on MSN1d
FDA Mandates ADHD Drug Labels To Warn Of Weight Loss Risk
The FDA now requires ADHD extended-release drug labels to warn of weight loss risks in children under 6, urging monitoring ...